In October, the Centers for Medicare and Medicaid Services directed carriers to again include three biologics in Medicare Part B coverage. (posted Nov. 19)
Search results for: Biologics
Meet the Model Biologics Policy
At its February meeting, the ACR board of directors approved the Model Biologics Policy, which will be used when discussing guidelines and patients’ quality of treatment with health insurance companies.
Integrating Immunology and Biologics into Clinical Practice
With the rapid expansion of new classes of medications, clinical practice has changed dramatically, and rheumatology health professionals must have a fundamental knowledge of immunology and the mechanisms of action of the biologic agents that have emerged with this expansion. Familiarity with the predrug screening recommended for biologic agents and the appropriate safety and disease monitoring necessary when a person uses these products is essential for the best patient outcomes. Additionally, being able to obtain drug plan authorization for use of biologics and being able to educate patients and their families or support team members about the financial considerations of these drugs helps to ensure best rheumatology practice.
Managing Office Infusions: From Biologics to Bones
On June 9, Josh Brinks, BSN, MSN, FNP, will address the management of office infusions during the ARHP June audioconference/webcast.
10 Things to Know about Lupus
SLE treatment is rapidly evolving as new therapies are developed & approved. Here are 10 key insights for clinicians.
Celebrating Interdisciplinary Collaboration: Pathways to Success
Four past ARP presidents mark the organization’s 60th anniversary by examining its evolution alongside significant challenges & opportunities in the field.
How the Experts Treat Sjögren’s Disease
With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.
Sjögren’s Dry Eye Requires Collaboration Among Eye Doctors, Rheumatologists
Sjögren’s dry eye requires collaboration between rheumatologists and ophthalmologists for optimal patient management and treatment of this quality-of-life issue.
Promising Phase 2 Results for Efgartigimod alfa-fcab in Adults with Primary Sjögren’s Disease
A study from Peene et al. found that patients with primary Sjögren’s disease experienced significant improvements in systemic disease activity and symptoms when treated with intravenous efgartigimod alfa-fcab.
What ASTP/ONC’s 2025 Regulations Mean for Rheumatologists
The ASTP/ONC’s recently updated United States Core Data for Interoperability Version 6 includes new data elements and applicable standards to support the provision of precision medicine and better patient care across the healthcare system.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 76
- Next Page »